Canadian anaplastic lymphoma kinase study: A model for multicenter standardization and optimization of ALK testing in lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 9, 2014, Pages 1255-1263

  Cutz, Jean Claude ^a   Craddock, Kenneth J ^b   Torlakovic, Emina ^b   Brandao, Guilherme ^c   Carter, Ronald F ^a   Bigras, Gilbert ^d   Deschenes, Jean ^d   Izevbaye, Iyare ^e   Xu, Zhaolin ^f   Greer, Wenda ^f   Yatabe, Yasushi ^g   Ionescu, Diana ^h   Karsan, Aly ^h   Jung, Sungmi ⁱ   Fraser, Richard S ⁱ   Blumenkrantz, Miriam ⁱ   Lavoie, Josee ⁱ   Fortin, Flechere ^j   Bojarski, Anna ^k   Côté, Gilbert B ^k   Van Den Berghe, Janette A ^l   Rashid Kolvear, Fariborz ^l   Trotter, Martin ^l   Sekhon, Harmanjatinder S ^m   Albadine, Roula ⁿ   Tran Thanh, Danh ⁿ   Gorska, Isabelle ⁿ   Knoll, Joan H M ^o   Xu, Jie ^d   Blencowe, Ben ^p   Iafrate, A John ^q   Hwang, David M ^b   Pintilie, Melania ^b   Gaspo, Rania ^r   Couture, Christian ^s   Tsao, Ming Sound ^b   more..

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^f DALHOUSIE UNIVERSITY   (Canada)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^j MCGILL UNIVERSITY   (Canada)

^k HEALTH SCIENCES NORTH   (Canada)

^l UNIVERSITY OF CALGARY   (Canada)

^m UNIVERSITY OF OTTAWA   (Canada)

ⁿ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^o LONDON HEALTH SCIENCES CENTRE   (Canada)

^p UNIVERSITY OF TORONTO   (Canada)

^q MASSACHUSETTS GENERAL HOSPITAL   (United States)

^r PFIZER INC   (United States)

^s LAVAL UNIVERSITY   (Canada)

more..

Author keywords

ALK testing; Fluorescence in situ hybridization; Immunohistochemistry; Reverse transcriptase polymerase chain reaction; Standardization

Indexed keywords

5A4 ANTIBODY; ACTIVIN RECEPTOR LIKE KINASE 1; ACTIVIN RECEPTOR LIKE KINASE 1 ANTIBODY; ANAPLASTIC LYMPHOMA KINASE; D5F3 ANTIBODY; UNCLASSIFIED DRUG; DNA; PROTEIN TYROSINE KINASE;

ARTICLE; CLINICAL ARTICLE; CONSENSUS; CONTROLLED STUDY; EPITHELIUM CELL; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; H SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MACROPHAGE; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; STANDARDIZATION; WILD TYPE; ADENOCARCINOMA; CANADA; CLINICAL TRIAL; ENZYMOLOGY; FEMALE; FOLLOW UP; GENETICS; LUNG NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY;

ADENOCARCINOMA; CANADA; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR PROTEIN-TYROSINE KINASES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84906258686     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000239     Document Type: Article

References (24)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
2. McLeer-Florin A, Moro-Sibilot D, Melis A, et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 2012;7:348-354.
3. Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013;19:4273-4281.
4. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-1019.
5. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.
6. Shaw TA, Mehra R, Kim DW, et al. Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. J Clin Oncology 2013;31:Abstract 8010.
7. Camidge DR, Bazhenova L, Salgia R, et al. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: updated results. J Clin Oncology 2013;31:Abstract 8031.
8. Tsao MS, Hirsch FR, Yatabe Y, et al. IASCL Atlas of ALK Testing in Lung Cancer. Aurora, CO: International Association for the Study of Lung Cancer; 2013.
9. Martinez P, Hernández-Losa J, Montero MÁ, et al. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS One 2013;8:e52261.
10. Minca EC, Portier BP, Wang Z, et al. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn 2013;15:341-346.
11. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010;16:1561-1571.
12. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011;6:459-465.
13. Paik JH, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011;6:466-472.
14. Vysis ALK Break Apart FFPE FISH Probe Kit Package Insert 30-608237/R2.
15. Wang R, Pan Y, Li C, et al. The use of quantitative real-time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res 2012;18:4725-4732.
16. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823-859.
17. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010;16:5581-5590.
18. Camidge DR, Skokan M, Kiatsimkul P, et al. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy. Cancer 2013;119:3968-3975.
19. Park HS, Lee JK, Kim DW, et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced nonsmall cell lung cancer patients. Lung Cancer 2012;77:288-292.
20. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-5223.
21. Zhang YG, Jin ML, Li L, et al. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues. PLoS One 2013;8:e64821.
22. Sholl LM, Weremowicz S, Gray SW, et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 2013;8:322-328.
23. Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2013;26:1545-1553.
24. Takamochi K, Takeuchi K, Hayashi T, Oh S, Suzuki K. A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients. PLoS One 2013;8:e69794.